CVIA Journal

Announcing a new article publication for Cardiovascular Innovations and Applications journal.  Transcatheter aortic valve implantation (TAVI) has emerged as the primary treatment strategy for severe symptomatic aortic stenosis (AS) in the older population (>75 years of age) with high-risk surgical profiles.

The growing older population and the concomitant age-related high prevalence of degenerative AS, combined with evidence of the non-inferiority of the TAVI procedure over surgical aortic valve replacement in intermediate-risk patients, increase the potential number of TAVI candidates. Concerns regarding the higher costs of TAVI than surgical aortic valve replacement are balanced by its shorter length of hospitalization and lower acute complication costs.

(more…)